laitimes

Shanghai Pharmaceutical: Not more than US$292.5 million to license SPH6162 overseas rights

author:Securities Times E Company

On the evening of October 28, Shanghai Pharmaceutical (601607) announced that the company will exclusively license the manufacturing, use, sale, import, development and commercialization rights of SPH6162 with independent intellectual property rights outside the Region of China (including Hong Kong, Macau and Taiwan) for a transaction amount of not more than US$292.5 million (in addition to sales commissions) to HUYABIO. The relevant rights and interests of SPH6162 in China remained owned by Shanghai Pharmaceutical. SPH6162 is an anti-tumor small molecule inhibitor independently developed by Shanghai Pharmaceutical Academia Sinica.

Read on